263 related articles for article (PubMed ID: 28711377)
1. Pancreas exocrine replacement therapy is associated with increased survival following pancreatoduodenectomy for periampullary malignancy.
Roberts KJ; Schrem H; Hodson J; Angelico R; Dasari BVM; Coldham CA; Marudanayagam R; Sutcliffe RP; Muiesan P; Isaac J; Mirza DF
HPB (Oxford); 2017 Oct; 19(10):859-867. PubMed ID: 28711377
[TBL] [Abstract][Full Text] [Related]
2. Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis.
Domínguez-Muñoz JE; Nieto-Garcia L; López-Díaz J; Lariño-Noia J; Abdulkader I; Iglesias-Garcia J
BMC Cancer; 2018 May; 18(1):534. PubMed ID: 29728096
[TBL] [Abstract][Full Text] [Related]
3. A model to predict survival following pancreaticoduodenectomy for malignancy based on tumour site, stage and lymph node ratio.
Dasari BV; Roberts KJ; Hodson J; Stevens L; Smith AM; Hubscher SG; Isaac J; Muiesan P; Sutcliffe RP; Marudanayagam R; Mirza DF
HPB (Oxford); 2016 Apr; 18(4):332-8. PubMed ID: 27037202
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study.
Roberts KJ; Bannister CA; Schrem H
Pancreatology; 2019 Jan; 19(1):114-121. PubMed ID: 30385188
[TBL] [Abstract][Full Text] [Related]
5. Does blood group affect survival following pancreatoduodenectomy for periampullary malignancy?
Khalil K; Bansal S; Ayaani S; Hodson J; Lam FT; Khan S; Ahmad J; Isaac J; Muiesan P; Mirza D; Dasari B; Marudanayagam R; Sutcliffe RP; Marangoni G; Roberts KJ
HPB (Oxford); 2018 Sep; 20(9):848-853. PubMed ID: 29705345
[TBL] [Abstract][Full Text] [Related]
6. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades.
He J; Ahuja N; Makary MA; Cameron JL; Eckhauser FE; Choti MA; Hruban RH; Pawlik TM; Wolfgang CL
HPB (Oxford); 2014 Jan; 16(1):83-90. PubMed ID: 23472829
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the effect of interval from presentation to surgery on outcome in patients with peri-ampullary malignancy.
Amr B; Shahtahmassebi G; Briggs CD; Bowles MJ; Aroori S; Stell DA
HPB (Oxford); 2016 Apr; 18(4):354-9. PubMed ID: 27037205
[TBL] [Abstract][Full Text] [Related]
8. Effect of Pancreatic Fistula on Recurrence and Long-Term Prognosis of Periampullary Adenocarcinomas after Pancreaticoduodenectomy.
Serrano PE; Kim D; Kim PT; Greig PD; Moulton CA; Gallinger S; Wei AC; Cleary SP
Am Surg; 2016 Dec; 82(12):1187-1195. PubMed ID: 28234183
[TBL] [Abstract][Full Text] [Related]
9. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer.
Saito T; Nakai Y; Isayama H; Hirano K; Ishigaki K; Hakuta R; Takeda T; Saito K; Umefune G; Akiyama D; Watanabe T; Takagi K; Takahara N; Hamada T; Uchino R; Mizuno S; Mouri D; Yagioka H; Kogure H; Togawa O; Matsubara S; Ito Y; Yamamoto N; Tada M; Koike K
Pancreas; 2018 Aug; 47(7):800-806. PubMed ID: 29851751
[TBL] [Abstract][Full Text] [Related]
10. Palliative pancreaticoduodenectomy in pancreatic and periampullary adenocarcinomas.
Wang SE; Shyr YM; Su CH; Chen TH; Wu CW
Pancreas; 2012 Aug; 41(6):882-7. PubMed ID: 22286381
[TBL] [Abstract][Full Text] [Related]
11. Exocrine pancreatic insufficiency following esophagectomy.
Huddy JR; Macharg FM; Lawn AM; Preston SR
Dis Esophagus; 2013 Aug; 26(6):594-7. PubMed ID: 23199208
[TBL] [Abstract][Full Text] [Related]
12. The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study.
Saito T; Hirano K; Isayama H; Nakai Y; Saito K; Umefune G; Akiyama D; Watanabe T; Takagi K; Hamada T; Takahara N; Uchino R; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
Pancreas; 2017 Mar; 46(3):341-346. PubMed ID: 28099252
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic enzyme replacement therapy following surgery for pancreatic cancer: An exploration of patient self-management.
Dunleavy L; Al-Mukhtar A; Halliday V
Clin Nutr ESPEN; 2018 Aug; 26():97-103. PubMed ID: 29908691
[TBL] [Abstract][Full Text] [Related]
14. Frequency of Appropriate Use of Pancreatic Enzyme Replacement Therapy and Symptomatic Response in Pancreatic Cancer Patients.
Barkin JA; Westermann A; Hoos W; Moravek C; Matrisian L; Wang H; Shemanski L; Barkin JS; Rahib L
Pancreas; 2019 Jul; 48(6):780-786. PubMed ID: 31210656
[TBL] [Abstract][Full Text] [Related]
15. Factors predicting adequate lymph node yield in patients undergoing pancreatoduodenectomy for malignancy.
Sierzega M; Bobrzyński Ł; Matyja A; Kulig J
World J Surg Oncol; 2016 Sep; 14(1):248. PubMed ID: 27644962
[TBL] [Abstract][Full Text] [Related]
16. Risk by indication for pancreaticoduodenectomy in patients 80 years and older: a study from the American College of Surgeons National Surgical Quality Improvement Program.
Bergquist JR; Shubert CR; Ubl DS; Thiels CA; Kendrick ML; Truty MJ; Habermann EB
HPB (Oxford); 2016 Nov; 18(11):900-907. PubMed ID: 27594118
[TBL] [Abstract][Full Text] [Related]
17. Prognostic indicators following curative pancreatoduodenectomy for pancreatic carcinoma: A retrospective multivariate analysis of a single centre experience.
Petrou A; Soonawalla Z; Silva MA; Manzelli A; Moris D; Tabet PP; Friend P
J BUON; 2016; 21(4):874-882. PubMed ID: 27685908
[TBL] [Abstract][Full Text] [Related]
18. Reclassification of tumour origin in resected periampullary adenocarcinomas reveals underestimation of distal bile duct cancer.
Pomianowska E; Grzyb K; Westgaard A; Clausen OP; Gladhaug IP
Eur J Surg Oncol; 2012 Nov; 38(11):1043-50. PubMed ID: 22883964
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic exocrine insufficiency after pancreaticoduodenectomy is more prevalent with pancreaticogastrostomy than with pancreaticojejunostomy. A retrospective multicentre observational cohort study.
Roeyen G; Jansen M; Ruyssinck L; Chapelle T; Vanlander A; Bracke B; Hartman V; Ysebaert D; Berrevoet F
HPB (Oxford); 2016 Dec; 18(12):1017-1022. PubMed ID: 27726974
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial.
Woo SM; Joo J; Kim SY; Park SJ; Han SS; Kim TH; Koh YH; Chung SH; Kim YH; Moon H; Hong EK; Lee WJ
Pancreatology; 2016; 16(6):1099-1105. PubMed ID: 27618657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
